Fig. 7.
Fig. 7. Inhibition of p85 and PAC1 but not total αIIbβ3 expression upon p85 antisense treatment. HEL and primary megakaryocytic cells were treated with p85 sense or antisense oligonucleotides for 3 days, while control cells were left untreated. (A) p85 protein and β-tubulin were sequentially detected on the same filter after SDS-PAGE and Western blotting with specific antibodies. Lanes: 1, untreated HEL cells; 2, HEL cells treated with p85 sense; 3, HEL cells treated with p85 antisense. m.w., molecular weights. The expression of activated and total αIIbβ3 was analyzed by FACScan with PAC1 or anti-CD41a MoAb, respectively, in primary megakaryocytic (B) and HEL (C) cells as described in Materials and Methods. Data are expressed as means ± SD of three separate experiments.

Inhibition of p85 and PAC1 but not total αIIbβ3 expression upon p85 antisense treatment. HEL and primary megakaryocytic cells were treated with p85 sense or antisense oligonucleotides for 3 days, while control cells were left untreated. (A) p85 protein and β-tubulin were sequentially detected on the same filter after SDS-PAGE and Western blotting with specific antibodies. Lanes: 1, untreated HEL cells; 2, HEL cells treated with p85 sense; 3, HEL cells treated with p85 antisense. m.w., molecular weights. The expression of activated and total αIIbβ3 was analyzed by FACScan with PAC1 or anti-CD41a MoAb, respectively, in primary megakaryocytic (B) and HEL (C) cells as described in Materials and Methods. Data are expressed as means ± SD of three separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal